BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23555261)

  • 1. TIM-3 does not act as a receptor for galectin-9.
    Leitner J; Rieger A; Pickl WF; Zlabinger G; Grabmeier-Pfistershammer K; Steinberger P
    PLoS Pathog; 2013 Mar; 9(3):e1003253. PubMed ID: 23555261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection.
    Elahi S; Niki T; Hirashima M; Horton H
    Blood; 2012 May; 119(18):4192-204. PubMed ID: 22438246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
    Yang R; Sun L; Li CF; Wang YH; Yao J; Li H; Yan M; Chang WC; Hsu JM; Cha JH; Hsu JL; Chou CW; Sun X; Deng Y; Chou CK; Yu D; Hung MC
    Nat Commun; 2021 Feb; 12(1):832. PubMed ID: 33547304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenic CD4
    Huang N; Zhou R; Chen H; Zhang S; Li J; Wei W; Sun J; Ren S; Li B; Deng H; Yang J; Ji F; Li Z
    Int J Immunopathol Pharmacol; 2021; 35():20587384211061051. PubMed ID: 34930041
    [No Abstract]   [Full Text] [Related]  

  • 5. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
    Huang YH; Zhu C; Kondo Y; Anderson AC; Gandhi A; Russell A; Dougan SK; Petersen BS; Melum E; Pertel T; Clayton KL; Raab M; Chen Q; Beauchemin N; Yazaki PJ; Pyzik M; Ostrowski MA; Glickman JN; Rudd CE; Ploegh HL; Franke A; Petsko GA; Kuchroo VK; Blumberg RS
    Nature; 2015 Jan; 517(7534):386-90. PubMed ID: 25363763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C.
    Osuch S; Laskus T; Berak H; Perlejewski K; Metzner KJ; Paciorek M; Radkowski M; Caraballo Cortés K
    Sci Rep; 2020 Sep; 10(1):16060. PubMed ID: 32994477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
    Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
    Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.
    Okoye I; Xu L; Motamedi M; Parashar P; Walker JW; Elahi S
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33310773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients.
    Shahbazi M; Moulana Z; Sepidarkish M; Bagherzadeh M; Rezanejad M; Mirzakhani M; Jafari M; Mohammadnia-Afrouzi M
    Microb Pathog; 2021 Apr; 153():104779. PubMed ID: 33548481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR5 and TIM-3 expressions define distinct exhausted T cell subsets in experimental cutaneous infection with
    Diupotex M; Zamora-Chimal J; Gajón JA; Bonifaz LC; Becker I
    Front Immunol; 2023; 14():1231836. PubMed ID: 37691941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulatory effect of Tim-3/Galectin-9 axis on T-cell-mediated immunity in pulmonary tuberculosis.
    Kang J; Wei ZF; Li MX; Wang JH
    J Biosci; 2020; 45():. PubMed ID: 32345786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma.
    Chen Z; Dong D; Zhu Y; Pang N; Ding J
    FASEB J; 2021 Mar; 35(3):e21401. PubMed ID: 33559190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-9 and VISTA Expression Define Terminally Exhausted T Cells in HIV-1 Infection.
    Shahbaz S; Dunsmore G; Koleva P; Xu L; Houston S; Elahi S
    J Immunol; 2020 May; 204(9):2474-2491. PubMed ID: 32205423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly proliferative and functional PD-1
    Batorov EV; Aristova TA; Pronkina NV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Shevela EY; Ostanin AA; Chernykh ER
    Int Immunopharmacol; 2021 Nov; 100():108093. PubMed ID: 34474273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
    Pagliano O; Morrison RM; Chauvin JM; Banerjee H; Davar D; Ding Q; Tanegashima T; Gao W; Chakka SR; DeBlasio R; Lowin A; Kara K; Ka M; Zidi B; Amin R; Raphael I; Zhang S; Watkins SC; Sander C; Kirkwood JM; Bosenberg M; Anderson AC; Kuchroo VK; Kane LP; Korman AJ; Rajpal A; West SM; Han M; Bee C; Deng X; Schebye XM; Strop P; Zarour HM
    J Clin Invest; 2022 May; 132(9):. PubMed ID: 35316223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
    Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
    Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
    Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for T cell immunoglobulin and mucin protein 3 and Toxascaris leonina galectin complex.
    Han CW; Jeong MS; Lee HN; Hwang EY; Jang SB
    Biochem Biophys Res Commun; 2024 Feb; 697():149544. PubMed ID: 38245927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of the TIM-3/Gal-9 immune checkpoint to tropical parasitic diseases.
    Bailly C
    Acta Trop; 2023 Feb; 238():106792. PubMed ID: 36509129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors.
    Muñoz-Muela E; Trujillo-Rodríguez M; Serna-Gallego A; Saborido-Alconchel A; Ruiz-Mateos E; López-Cortés LF; Gutiérrez-Valencia A
    Biomed Pharmacother; 2023 Dec; 168():115750. PubMed ID: 37871555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.